Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa

FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.

FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.

Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.